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Traumatic brain injury (TBI) causes transient increases and subsequent decreases in
brain glucose utilization. The underlying molecular pathways are orchestrated processes
and poorly understood. In the current study, we determined temporal changes in cortical
and hippocampal expression of genes important for brain glucose/lactate metabolism
and the effect of a known neuroprotective drug telmisartan on the expression of these
genes after experimental TBI. Adult male C57BL/6J mice (n = 6/group) underwent sham
or unilateral controlled cortical impact (CCI) injury. Their ipsilateral and contralateral
cortex and hippocampus were collected 6 h, 1, 3, 7, 14, 21, and 28 days after injury.
Expressions of several genes important for brain glucose utilization were determined by
qRT-PCR. In results, (1) mRNA levels of three key enzymes in glucose metabolism [hexo
kinase (HK) 1, pyruvate kinase, and pyruvate dehydrogenase (PDH)] were all increased
6 h after injury in the contralateral cortex, followed by decreases at subsequent times in
the ipsilateral cortex and hippocampus; (2) capillary glucose transporter Glut-1 mRNA
increased, while neuronal glucose transporter Glut-3 mRNA decreased, at various times
in the ipsilateral cortex and hippocampus; (3) astrocyte lactate transporter MCT-1 mRNA
increased, whereas neuronal lactate transporter MCT-2 mRNA decreased in the ipsilateral cortex and hippocampus; (4) HK2 (an isoform of hexokinase) expression increased
at all time points in the ipsilateral cortex and hippocampus. GPR81 (lactate receptor)
mRNA increased at various time points in the ipsilateral cortex and hippocampus. These
temporal alterations in gene expression corresponded closely to the patterns of impaired
brain glucose utilization reported in both TBI patients and experimental TBI rodents. The
observed changes in hippocampal gene expression were delayed and prolonged, when
compared with those in the cortex. The patterns of alterations were specific to different

Frontiers in Endocrinology | www.frontiersin.org

1

September 2017 | Volume 8 | Article 231

Zhou et al.

Brain Metabolic Genes After TBI

brain regions and exhibited different recovery periods following TBI. Oral administration
of telmisartan (1 mg/kg, for 7 days, n = 10 per group) ameliorated cortical or hippocampal mRNA for Glut-1/3, MCT-1/2 and PDH in CCI mice. These data provide molecular
evidence for dynamic alteration of multiple critical factors in brain glucose metabolism
post-TBI and can inform further research for treating brain metabolic disorders post-TBI.
Keywords: gene expression, glucose metabolism, lactate, hexokinase, GPR81, angiotensin II AT1 receptor,
telmisartan, traumatic brain injury

INTRODUCTION

monocaboxylate transporters (MCT-1 and MCT-2) (15, 18, 19).
HK2 (an isoform of hexokinase) and GPR81 (lactate receptor)
are also important in brain glucose metabolism, especially in
the injured brain. HK2 expression has been identified in the
outer membrane of mitochondria in most brain area and is
related to abnormal glycolysis during hypoxia and apoptosis
(20). Lactate-activated GPR81 affects several biological pathways in the injured brain, including brain glucose metabolism
(21–23). The expression of these enzymes and transporters in
various brain tissues is vulnerable to primary and secondary
brain injuries.
Several prior reports suggest how various types of TBI influence expression of these enzymes and transporters individually
(24–26). In addition, gene array and proteomics studies have
examined the expression of large numbers of genes or proteins,
including the aforementioned enzymes/transporters, predominantly within a single brain region and/or at a single time
point after experimental TBI (27–30). Because brain glucose
metabolism is an orchestrated interplay, more fundamental
questions remain to be answered. How does TBI simultaneously influence gene expression of multiple key enzymes/transporters that span the gamut of glucose-associated metabolic
processes? Also, how does TBI-mediated gene expression vary

Glucose is an essential fuel for maintaining cellular functions.
In particular, the brain uses glucose and its related intermediate metabolites as energetic substrates to support its functions.
Under most normal and pathological conditions, brain glucose
utilization is well preserved by complex mechanisms, regardless
of peripheral glucose fluctuations.
Following traumatic brain injury (TBI), various brain tissues undergo two types of injuries. The primary injury results
from direct mechanical damage to the brain. Subsequently,
secondary injury elicits a series of pathophysiological cascade,
including edema, increased intracranial pressure, hemorrhage,
and decreased cerebral blood flow. Cellular processes during the
secondary injury phase involve excessive release of excitatory
neurotransmitters, activation of ion channels, mitochondrial
dysfunction, hypoxia, and inflammation (1, 2), all leading to
degradation of cellular structures, apoptosis (3), and affecting
brain glucose requirements and utilization (4, 5). In fact, TBI
consistently triggers transient increases and prolonged decreases
in brain glucose utilization, as assessed by brain imaging in both
TBI patients and experimental animals (6–12).
Our current understanding of molecular processes related
effects of TBI on brain glucose utilization is limited. This limitation poses a critical barrier in developing potential therapeutic
strategies for TBI management. Among more than 300 currently
registered human clinical trials targeting to drug intervention
of TBI, there are fewer than 10 trials targeted to normalize
brain glucose utilization, and the intervention compounds
used in these trials are limited to insulin or glucose/lactate
(13). In contrast, several classes of FDA-approved pharmacological agents improve peripheral tissue glucose utilization,
with clearly identified mechanisms. A better understanding of
molecular mechanisms related to brain glucose utilization after
TBI will accelerate investigations of these agents regarding their
potential similar effect(s) in the posttraumatic-injured brain.
Brain glucose utilization requires glucose transport and
metabolism, as schematized in Figure 1. Glucose transporters
(Glut-1 and Glut-3) transport glucose from capillaries to astrocytes and/or neurons (14, 15). Several rate-limiting enzymes
play critical roles in glucose metabolism, such as hexokinase
1 (HK1), pyruvate kinase (PK), and pyruvate dehydrogenase
(PDH). Additionally, neurons use lactate as an energy substrate to produce ATP (16, 17). Lactate can be produced by
glycogenolysis in astrocytes and transported to neurons via
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Figure 1 | Schematized brain glucose utilization among capillaries,
astrocytes and neurons. HK, hexokinase; PK, pyruvate kinase; PDH,
pyruvate dehydrogenase; Glut-1, capillary glucose transporters 1; Glut-3,
neuronal glucose transport 3; MCT-1, astrocyte monocaboxylate (lactate)
transporters 1; MCT-2, neuronal monocaboxylate (lactate) transporters 2.
GPR81 (G protein-coupled receptor 81 or hydrocarboxylic acid receptor 1,
serve as lactate receptor when lactate is used for signaling molecule).
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in diverse brain regions during progression of and recovery
from TBI?
In the current studies, we used a controlled cortical impact
(CCI) injury mouse model of TBI to investigate: (1) temporal
changes in gene expression of selected enzymes and transporters
known to be critical for brain glucose utilization, (2) whether a
known neuroprotective agent, telmisartan, ameliorates alterations in expression of the abovementioned genes following CCI.
Telmisartan is an FDA-approved drug and was originally used
for treatment of hypertension, based upon its activity as an
angiotensin II AT1 receptor blocker (ARB). Telmisartan also
activates peroxisome proliferator-activated receptor gamma
(PPARγ), which improves peripheral tissue glucose utilization
(31). Neuroprotective effects of telmisartan have recently been
reported and are thought to be mediated in part by activating
PPARγ (32–35). Because of the complex pathogenesis of TBI,
optimized therapies for TBI should target several coexisting
pathological mechanisms (36). Considering pleiotropic actions
of telmisartan on TBI and glucose metabolism, we examined
its effects on expression of genes that regulate to brain glucose
utilization in a TBI mouse model.
In study 1, we examined expression of a set of genes related
to glucose metabolism at multiple time points to determine
if the temporal changes in mRNA expression were related to
the temporal changes in brain glucose metabolism after brain
injury. These points are chosen to represent early and secondary injuries phases following TBI. In study 2, we examined
if gene expression affected by TBI would be ameliorated by
telmisartan at a single time point that was selected based on
results from study 1. Cortex and hippocampus are the two
brain regions that are directly injured or located immediately
underneath the injured cortex in our CCI mouse model. Thus,
tissues from these two regions contralateral and ipsilateral
to the injury were selected for measuring expression of the
aforementioned genes.
Our ultimate goal is to develop much needed new therapeutic options for TBI. Data from the current studies will inform
subsequent mechanistic studies and broaden our selection of
other drugs for their potential role on impaired brain glucose
metabolism following TBI.

a dwell time of 0.1 s, an impact depth of 2.0 mm, and an impactor tip with 3.5 mm diameter. All mice were anesthetized with
isoflurane (induction at 4% and maintenance at 2%) evaporated
in oxygen and administered through a nose mask. Anesthesia
depth was monitored by assessing respiration rate and pedal
withdrawal reflexes. The mice were placed on a custom-made
stereotaxic frame with a built-in heating bed that maintained
body temperature at 37°C. After injury, the incisions were closed
with staples, anesthesia was terminated, and the animals were
placed in heated cages to maintain normal core temperature
for 45 min postinjury. Sham-injured mice underwent the same
procedures, including anesthesia, stereotaxic mounting, skin and
fascia reflection, and incision closing with staples, but a cranial
window was not introduced as we consider this to be part of the
primary injury sequence in the CCI model.
In experiment 1, mice were decapitated without isoflurane
anesthesia at seven different time points (6 h, 1, 3, 7, 14, 21, and
28 days) after CCI or sham injury (n = 6 per group). In experiment
2, mice were divided into vehicle or telmisartan groups after CCI
or sham injury (n = 10/group, a total of four groups). Telmisartan
(Sigma-Aldrich, 1 mg/kg, dissolved in 1% DMSO diluted in distilled water) or vehicle (1% DMSO diluted in distilled water) were
administered by oral gavage at a volume of 5 mL/kg. Telmisartan
was administrated 1 h post-CCI or sham injury, and once per day
for the following 6 days. The experiment was ended 7 days after
CCI or sham injury.
For both CCI- and sham-injured mice, the ipsilateral and
contralateral parietal cortex and hippocampus were dissected
and immediately placed in RNAlater® Solution (Ambion,
Thermo Fisher Scientific) and stored at −20°C for total RNA
extraction.
The following verifications were performed to ensure
accuracy of the real-time PCR TaqMan® method. (1) The same
samples were tested with or without DNase treatment for each
of the nine target genes (Table 1) to eliminate possible genomic
DNA contamination. (2) Standard curves (range from 0.122
to 250 ng/µL total RNA) were assessed for all nine genes to
verify the sufficiency and specificity of PCR amplifications for
each target gene. The slopes of standard curves were all within
a 3.0–3.6 range, and coefficients of determination (R2) were all

MATERIALS AND METHODS

Table 1 | Brain glucose/lactate utilization related genes.

Animals and CCI Injury

Gene name

All animal protocols were approved by the Georgetown
University Animal Care and Use Committee and followed
National Institutes of Health standards.
Healthy, intact male C57BL/6J mice, aged 8 weeks (Jackson
Laboratories, Bar Harbor, ME, USA) were group housed at
room temperature of 22 ± 1°C with a 12-h light/dark cycle and
ad libitum access to food and water. Mice were habituated to
the environmental conditions for 7 days. The CCI injury was
induced over the parietal cortex as previously described, and
was considered to elicit moderate TBI (37). Briefly, the brain is
injured by rigid impactor to an intact dura exposed following a
craniectomy on the left cortex. The following parameters were
used to control impact severity: an impact velocity of 5.25 m/s,
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TagMan gene expression ID

Function
Hexokinase 1

Hk1

Mm00439344_m1

PK

Mm00834102_gH

Pyruvate kinase

PDH

Mm00499323_m1

Pyruvate dehydrogenase

Slc2a1

Mm00441480_m1

Glut-1: capillary glucose
transporter

Slc2a3

Mm00441483_m1

Glut-3: neuronal glucose
transporter

Slc16a1

Mm01306379_m1

MCT-1: astrocyte lactate
transport

Slc16a7

Mm00441442_m1

MCT-2: neuronal lactate
transporter

GPR81

Mm00558586_s1

lactate receptor

Hk2

Mm00443385_m1

Hexokinase isoform 2
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CCI, one-way ANOVA was used to compare TBI and sham group
at the 6 h time point only.
For study 2, data were analyzed by T-test. Comparison was
made within the same injury sides (contralateral or ipsilateral)
and the same drug treatment (vehicle or telmisartan).

larger than 0.99, as required by the TaqMan® real-time PCR
assay (3). Because target gene expression must be normalized
using endogenous housekeeping genes, it was essential that the
endogenous control genes used were not altered by TBI. We
tested six different candidate endogenous housekeeping genes
(Table 2) in samples collected at different time points after CCI
to ensure that the expression level of selected housekeeping
gene was stable and not altered by the injury. The variances in
expression levels among those samples were calculated for each
candidate housekeeping gene (data not shown). The gene with
the smallest variance (cyclophilin) was selected for use as the
endogenous housekeeping gene. Our results were consistent
with a prior publication regarding selection of an endogenous
housekeeping gene in mice after experimental TBI (38). To
eliminate possible error caused by sample pipetting and differences in RNA quantity and efficiency of reverse transcription
for each sample, we established a multiplex q-PCR method for
all genes listed in Table 1. Each tested gene was measured in
the separate reaction alone, and with cyclophilin, to verify that
there was no significant primer dimer formation. The detailed
real-time PCR TaqMan® condition was the same as the protocol provided by Applied Biosystems (39). The probes for each
target gene and cyclophilin were labeled with FAM and VIC,
respectively.
After the qRT-PCR method was verified as described above,
total RNA was extracted from the dissected tissues using the
Trizol reagent following the manufacturer’s protocol, and
expression of nine different genes (Table 1) in cortex and hippocampus both ipsilateral and contralateral to the injury were
measured by the multiplex q-PCR method. A comparative Ct
(ddCt) method was used to determine gene expression levels
for each sample.

RESULTS
Expression of Genes That Encode Critical
Enzymes for Glucose Metabolism

Hexokinase 1, PK, and PDH are three rate-limiting enzymes
that play critical roles in glucose metabolism (Figures 1 and 2).
mRNA expressions of all three of these enzymes were significantly altered after CCI (Figure 2). However, the alterations differed in regard to brain region, site of injury, and time postinjury.
mRNA levels of HK1, PK, and PDH all increased early (6 h) after
injury in the contralateral cortex, and all decreased at various
subsequent time points in the ipsilateral cortex and hippocampus. Moreover, the observed decreases in the ipsilateral side
were kinetically delayed in the hippocampus when compared
to those in the cortex. For HK1, the decreases occurred from
day 1 to day 7 in the cortex (P < 0.05) and from day 3 to day 28
in the hippocampus (P < 0.05). For PK, the decreases occurred
from 6 h to day 14 in the cortex (P < 0.05) and from day 7 to
day 28 in the hippocampus (P < 0.05). For PDH, the decreases
occurred from day 1 to day 7 in the cortex (P < 0.01) and from
day 7 to day 28 in the hippocampus (P < 0.05). In contrast
to these ipsilateral decreases, the expression of HK1, PK, and
PDH in the contralateral cortex all increased 6 h postinjury
(P < 0.05 for HK1, PK, and P < 0.01 for PDH) and returned
to the level of sham controls by day 1 after injury. The only
exception was the level of PDH mRNA in the contralateral
cortex, which also had transient increase at day 3 postinjury
(P < 0.05). As expected, in the contralateral hippocampus, none
of the three genes exhibited altered expression at any time point
following CCI. Together, these results demonstrated that the
alterations observed on the ipsilateral side recovered in the
cortex within days after injury, but persisted significantly longer
in the hippocampus.

Statistical Analysis

Data are presented as mean values ± SEM. SAS 9.2 was used for
all analyses. P < 0.05 was considerate statistically significant.
For study 1, results were expressed as the percentage change
over their corresponding control samples, which were collected
at corresponding time points and corresponding (ipsilateral or
contralateral) sites from sham-injured mice. Data were analyzed
by two-way ANOVA with treatment (Sham vs. TBI) and time
post-CCI as two independent factors. Because observed temporal
changes varied for different genes and injured sides, the time
frames used for calculating TBI effects differed, as specified in
the Results section. For those genes that exhibited opposite trends
of alterations at 6 h, compared with all other time points following

Expression of Genes That Encode Critical
Glucose Transporters

Glut-1 is a capillary glucose transporter and Glut-3 is a neuronal
glucose transporter. In the contralateral cortex and hippocampus, expression of both Glut-1 and Glut-3 mRNAs increased
at 6 h and returned to sham levels by day 1 following injury
(P < 0.05) (Figure 3). However, in the ipsilateral cortex and
hippocampus, CCI-affected Glut-1 and Glut-3 gene expression
in an opposite manner. Glut-1 increased from 6 h to day 7 in
the cortex (P < 0.01) and from 6 h to day 21 in the hippocampus (P < 0.01). Glut-3 decreased from day 3 to day 7 in the
cortex (P < 0.05) and from day 3 to day 28 in the hippocampus
(P < 0.01), despite transient increases at 6 h (P < 0.01 for both
cortex and hippocampus). These data suggest that CCI affects
the mRNAs of these two glucose transporters in opposite directions, based on their cellular locations. In general, capillary

Table 2 | Housekeeping genes tested.
Gene name

TagMan gene expression ID

Elf1
Pop4
Polr2a
B2m
Tfrc
Cyclophilin

Mm00468217_m1
Mm00481282_m1
Mm00839493_m1
Mm00437762_m1
Mm00441941_m1
Custom designed (40)
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Figure 2 | Hexokinase (HK), pyruvate kinase (PK), and pyruvate dehydrogenase (PDH) mRNA levels in the cortex and hippocampus measured at different time
points postcontrolled cortical impact (post-CCI). Data are mean ± SEM (n = 3–6 per group at each time point for each group). #: P < 0.05, contralateral cortex of
injured mice compared with the corresponding tissue of sham-injured mice at indicated single time points. Solid brackets indicate the comparison between
ipsilateral side of cortex/hippocampus of CCI mice and the corresponding tissue obtained from sham operated mice.

located Glut-1 mRNA increased, while neuronal located Glut-3
decreased.

MCT-2 mRNA decreased, and the duration and timing of the
decreases were distinctive to injury sides. On the contralateral
side, decreases in MCT-2 were only observed at day 1 postinjury for cortex (P < 0.05) and hippocampus (P < 0.01). On
the ipsilateral side, decreases in MCT-2 were persistent from
6 h to day 28 postinjury in both cortex (P < 0.01) and hippocampus (P < 0.01). We also observed a trend to decreased
MCT-2 mRNA returning to sham level in the cortex (time effect
P < 0.01 by two way ANOVA), but not in the hippocampus.

Expression of Genes That Encode Critical
Lactate Transporters

MCT-1 is an astrocyte lactate transporter and MCT-2 is a
neuronal lactate transporter. MCT-1 mRNA increased substantially in both cortex and hippocampus, regardless of injury side
(P < 0.01) (Figure 4). In contrast to these increases in MCT-1,
Frontiers in Endocrinology | www.frontiersin.org
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Figure 3 | Glut-1and Glut-3 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical impact (post-CCI). Data are
mean ± SEM (n = 3–6 per group at each time point for each group). #: P < 0.05, contralateral cortex/hippocampus of injured mice compared with corresponding
tissue obtained from sham-operated mice at indicated single time points. **, P < 0.01, ipsilateral cortex/hippocampus of injured mice compared with corresponding
tissue obtained from sham-operated mice at indicated single time points. Solid brackets indicate the comparison between the ipsilateral side of cortex/hippocampus
from CCI mice and corresponding tissue obtained from sham-operated mice.

28 in the cortex (P < 0.01) and from day 7 to day 28 in the hippocampus (P < 0.05) post-TBI. On the contralateral side, GPR81
mRNA increased only at day 28 postinjury in the hippocampus
(P < 0.05), but not in the cortex.

Therefore, similar to glucose transporters, CCI also affected
these two lactate transporters’ mRNA in opposite directions
based on their cellular locations. In general, mRNA of MCT-1
located in astrocytes increased, while mRNA of MCT-2 located
in neurons decreased.

Telmisartan Selectively Ameliorated
CCI-Affected Gene Expression of
Glut-1/3, MCT-1/2, and PDH

Expression of Genes That Encode HK2
and Lactate Receptor GPR81

From study 1, we found CCI increased gene expression for
capillary glucose transporter Glut-1 and astrocyte lactate
transporter MCT-1 and decreased gene expression for neuronal
glucose transporter Glut-3 and lactate transporter MCT-2 in the
ipsilateral side of both cortex and hippocampus (Figures 3 and
4). Such effects were confirmed in study 2 (Figures 3 and 4).
However, telmisartan gavage at a dosage of 1 mg/kg for 7 days
partially reversed the alterations of Glut-1 and Glut-3 in the
ipsilateral cortex and hippocampus (Figure 6). For lactate transporters, telmisartan prevented increased MCT-1 expression in
the contralateral, but not ipsilateral, hippocampus (Figure 7B).
Compared to MCT-1, the decreased gene expression of MCT-2

Hexokinase 2 mRNA was dramatically increased at all time
points in both cortex and hippocampus, regardless of injury sides
(P < 0.01), except at 6 h time point on the contralateral side of
hippocampus (Figure 5). The increased HK2 expression peaked
at day 3 or day 7 postinjury on the ipsilateral cortex and hippocampus, respectively. Notably, among all the genes examined,
the ipsilateral increases of HK2 mRNA were the most dramatic:
600% and 1,200% above the sham levels in cortex and hippocampus, respectively.
Controlled cortical impact also increased expression of
GPR81 mRNA in an injury side and time specific manner. On
the ipsilateral side, GPR81 mRNA levels increased from 6 h to day
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Figure 4 | Monocaboxylate transporter (MCT)-1 and MCT-2 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical
impact (post-CCI). Data are mean ± SEM (n = 3–6 per group at each time point). # or ## P < 0.05 or P < 0.01, contralateral cortex or hippocampus of injured mice
compared with corresponding tissue obtained from sham-operated mice at indicated single time points. Solid brackets indicate the comparison between the
ipsilateral side of the cortex or hippocampus from CCI-injured mice and the corresponding tissue obtained from sham-operated mice. Dashed brackets indicate the
comparison between contralateral sides of the cortex or hippocampus from CCI-injured mice and the same sides of corresponding tissue obtained from shamoperated mice.

was small and were prevented by telmisartan in the ipsilateral
hippocampus (Figure 7D).
We also measured HK1, PK, PDH, HK2, and GPR81 gene
expression in the contralateral and ipsilateral sides of both
cortex and hippocampus. Telmisartan partially reversed the
CCI-induced changes in ipsilateral hippocampal PDH mRNA
levels, but not other alterations caused by CCI, 7 days postinjury
(Table 3).

the need for short-term increases in brain glucose utilization
immediately following TBI reported previously (6, 7). At various
subsequent time points, we observed decreased mRNA expression for HK1, PK, and PDH in the ipsilateral cortex and hippocampus. HK1, PK, and PDH protein levels have been reported
to decrease following different types of TBI (29, 43, 44). Thus, our
observed decreases in mRNA of three critical enzymes agree with
previously reported relative protein changes and the prolonged
decreases in brain glucose metabolism.
Interestingly, mRNA for both glucose and lactate transporters
changed in opposite directions, depending on the locations of
these transporters. Glut-1, predominantly expressed in capillaries (14, 15), increased; whereas neuronal Glut-3 decreased
in the ipsilateral cortex and hippocampus. Similarly, lactate
transporter MCT-1, predominantly located in astrocytes (15,
18, 19), increased; whereas neuronal lactate transporter MCT-2
decreased in the ipsilateral cortex and hippocampus. These findings suggest that the sustained impairments in brain glucose utilization following TBI may be neuron-specific, despite stimulated

DISCUSSION
The temporal alterations in gene expression we observed in these
brain areas corresponded closely to transient early increases
and subsequent decreases in brain glucose utilization reported
in humans and experimental animals following various types of
TBI injury (6–12, 41, 42). Six hours after CCI, mRNA levels for
two glucose transporters (Glut-1 and Glut-3) and three critical
enzymes (HK1, PK, and PDH) were all significantly increased in
contralateral brain area. These transient increases might reflect
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Figure 5 | An isoform of hexokinase (HK2) and GPR81 mRNA levels in the cortex and hippocampus measured at different time points postcontrolled cortical
impact (post-CCI). Data are mean values ± SEM (n = 3–6 per group at each time point). Solid brackets indicate the comparison between ipsilateral sides of the
cortex or hippocampus from CCI-injured mice and the corresponding tissue obtained from sham-operated mice. Dashed brackets indicate the comparison between
contralateral sides of the cortex or hippocampus from CCI-injured mice and the same side of corresponding tissue obtained from sham-injured mice.

expressions of glucose and lactate transporters in capillary and
astrocytes. One possible explanation might relate to neuronal
susceptibility to death and neuronal loss immediately after injury
of the ipsilateral hemisphere. Further research on cell-specific
glucose metabolism appears warranted to enhance our understanding of TBI impaired brain glucose utilization.
Changes in hippocampal gene expression were both delayed
and prolonged, when compared with those in the cortex. This
finding agrees with clinical observations that the hippocampus exhibits prolonged impairments in glucose metabolism
when compared with other brain regions, as detected by
positron emission tomography (11). For all three key glucose
metabolism-related enzymes tested in the current study, their
mRNA alterations returned to or toward normal shortly after
injury in the cortex. In contrast, alterations of the same three
genes persisted for the duration of study in the hippocampus.
The underlying molecular mechanisms responsible for these
kinetic and tissue-specific changes likely involve multiple
factors. One possible factor is permeability of gap junctions,
which are intercellular channels connecting the cytoplasm of

Frontiers in Endocrinology | www.frontiersin.org

two cells. These neuronal gap junctions are critically important in the secondary neuronal death following CCI (45). The
observation that the gap junctions in the hippocampus are significantly more permeable than those in the cortex (46) might
explain why the hippocampus appears to be more vulnerable to
harmful molecules resulted from the secondary injury following TBI. Our data also suggest that the delayed and prolonged
alteration of these genes in hippocampus may be a cause of
the corresponding protracted effects of TBI on memory. Such
hypothesis needs to be confirmed by further studies on longer
periods after TBI.
The finding of dramatically increased HK2 mRNA expression both contralateral and ipsilateral to the injured cortex
and hippocampus was unexpected. HK2 is an isoform of
hexokinase. Unlike HK1, the temporal changes of HK2
mRNA expression suggest hypoxia and apoptosis related to
abnormal glycolysis (20). Up-regulation of HK2 mRNA is
typically associated with aerobic glycolysis rather than oxidative phosphorylation to generate ATP (47), possibly due to the
activation of neuroinflammatory responses in microglia and
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Figure 6 | Telmisartan ameliorated controlled cortical impact (CCI)-affected gene expression for Glut-1 and Glut-3. mRNA of capillary glucose transporter Glut-1
(A,B) and neuronal glucose transporter Glut-3 (C,D) were increased or decreased 7 days after CCI in ipsilateral sides of cortex and hippocampus of mice (n = 10/
group). Telmisartan (1 mg/kg) revised these changes. *P < 0.05 traumatic brain injury (TBI) vs. Sham.

astrocytes (48). Moreover, HK2 expression was associated with
poor prognosis and worse overall survival of glioma patients
(47, 40, 49). Following CCI, HK2 expression peaked at day
3 or day 7 postinjury and remained two-fold elevated above
sham levels at the end of study. These dynamic features and
relevance to the recovery process suggest that HK2 mRNA
may serve as a biomarker to monitor the progress of injury and
recover following TBI. Further studies will determine whether
detection of HK2 mRNA in neuron-specific exosomes isolated
from peripheral blood can serve as a candidate biomarker for
monitoring the progress of TBI.
GPR81 is a G protein-coupled receptor activated by lactate
(22, 50, 51). Brain lactate concentrations are significantly
increased following TBI (52). The increased lactate can serve
both as an alternative brain energetic fuel, and as a signaling
molecule affecting several biological pathways in the injured
brain (22, 23, 53). Overexpression of GPR81 has been shown to
increase cell vulnerability to ischemic injury, whereas inhibition
of GPR81 prevented neuronal cell death and reversed brain
ischemia-induced apoptosis (53). Thus, GPR81 antagonism has
been suggested as a possible therapeutic strategy for the treatment of cerebral ischemia (54). Of note, GPR81 also participates
in lactate related neuronal protection initiated by acute organ
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injury (21, 22, 55). Our findings suggest that use of lactate as
a supplementary fuel following brain injury (56, 57) may have
complicated consequences. The timing, benefits and harm of such
approach requires further investigation.
In brief, CCI-induced alterations in gene expression were
specific for the injury side and postinjury time. One possible
explanation is that the secondary injury may radiate from initial
injury site like a wave to adjacent tissues. Thus, in general, alterations contralateral to the injury were less severe than those ipsilateral to the injury, except at 6 h. Also, alterations in hippocampal
gene expression were both delayed and prolonged compared with
those in the cortex. These results were of interest because they
allow visualization of changes that code most important factors
in glucose metabolism.
Telmisartan and other ARBs are strongly neuroprotective
in many rodent models of brain disorders, including TBI
(35, 58–62) In experimental TBI, telmisartan reduced inflammation and neuronal injury and protected cognition (35,
63–71), effects mediated in part by activating PPARγ (32–35).
Telmisartan has also been assessed in patients with Alzheimer’s
disease in an NIH approved clinical trial (72). Although
telmisartan improved glucose utilization in human peripheral
tissues and olfactory tracts (73, 74), its effects on normalizing
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Figure 7 | Telmisartan ameliorated controlled cortical impact (CCI)-affected gene expression for MCT-1 and MCT-2. mRNA of astrocyte lactate transporter MCT-1
(A,B) and neuronal lactate transporter MCT-2 (C,D) were increased or decreased 7 days after CCI in ipsilateral or contralateral sides of cortex and hippocampus of
mice (n = 10/group). Telmisartan (1 mg/kg) revised these changes. *P < 0.05 traumatic brain injury (TBI) vs. Sham.

glucose metabolic-related pathways post-TBI have not been
reported. In the current study, we observed that telmisartan
improved some, but not all alterations in gene expression
7 days post-TBI. Primarily, CCI-induced changes in mRNAs
for glucose/lactate transporters impaired by CCI were partially
improved by telmisartan, as well as mRNA for one of three genes
encodes critical enzymes related to glucose metabolism. These
improvements were only detected when comparison was made
between telmisartan-treated Sham vs. TBI groups, not between
vehicle-treated TBI vs. telmisartan-treated TBI groups. How
these improvements interact with other known neuroprotective
pathways require further investigation.
The current findings represent an initial step in our research
and need to be complemented, in further studies, with data
integrating gene expression with protein levels and glucose
utilization. We did not examine the temporal alterations in
behavior, biochemistry or histology in this mouse model,
as those data have been previously published by our group
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(37, 58–60). It should also be noted that longitudinal recovery
from TBI-induced brain metabolic depression has been related
to recovery of behavioral dysfunction assessed by the Morris
Water Maze performance (12).
In summary, we measured temporal changes in gene
expression of crucial factors that span the interacting pathways
associated with glucose metabolism in two key brain regions
after CCI in adult mice. The observed temporal alterations in
gene expression corresponded closely to temporal alterations
in brain glucose utilization reported in TBI patients and
experimental animals (6–12). TBI-mediated changes in gene
expressions persisted longer in hippocampal vs. cortical tissues
and some of those alterations in gene expression were ameliorated by the neuroprotective agent telmisartan. These results
will inform subsequent more comprehensive investigations on
development of pharmacological interventions that can target
the dynamic interplay in brain glucose metabolic disorders
following TBI.
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Table 3 | Gene expression of HK1, PK, PDH, HK2, and GPR81 measured 7 days post-TBI.
Tissue

Drug

Treat

HK1

Contralateral cortex

Vehicle

Sham
TBI
Sham
TBI

1.40 ± 0.06
1.32 ± 0.05
1.40 ± 0.06
1.31 ± 0.06

4.96 ± 0.18
5.04 ± 0.22
4.52 ± 0.42
4.59 ± 0.20

4.75 ± 0.37
4.62 ± 0.26
4.65 ± 0.25
4.83 ± 0.31

8.2 ± 0.81
14.3 ± 4.3**
7.9 ± 0.43
11.4 ± 0.9**

10.31 ± 1.32
15.94 ± 3.29
10.53 ± 1.14
11.74 ± 1.28

Sham
TBI
Sham
TBI

1.54 ± 0.12
1.35 ± 0.03*
1.53 ± 0.10
1.34 ± 0.06*

3.46 ± 0.26
3.77 ± 0.18
3.72 ± 0.23
3.64 ± 0.29

4.78 ± 0.54
4.36 ± 0.34
4.55 ± 0.35
4.83 ± 0.46

6.5 ± 0.60
53.3 ± 11.3**
13.6 ± 6.16
34.1 ± 5.2**

7.06 ± 2.02
16.79 ± 1.7**
7.92 ± 1.19
15.73 ± 1.9**

Sham
TBI
Sham
TBI

1.86 ± 0.10
1.92 ± 0.10
1.97 ± 0.46
2.09 ± 0.06

5.90 ± 0.51
6.58 ± 0.40
6.04 ± 0.31
6.03 ± 0.34

9.79 ± 0.88
10.36 ± 0.59
9.78 ± 0.70
10.50 ± 0.52

13.9 ± 1.57
32.5 ± 4.4**
9.9 ± 1.21
27.2 ± 2.7**

22.13 ± 3.23
27.40 ± 3.84
23.30 ± 2.56
31.43 ± 5.17

Sham
TBI
Sham
TBI

1.77 ± 0.10
1.57 ± 0.07*
1.80 ± 0.46
1.58 ± 0.06*

6.75 ± 0.34
6.63 ± 0.39
6.25 ± 0.51
6.61 ± 0.27

11.7 ± 0.56
62.3 ± 10.6**
11.0 ± 0.41
75.6 ± 5.4**

17.65 ± 2.54
31.47 ± 6.16*
19.40 ± 2.66
27.08 ± 4.57*

Telmisartan
Ipsilateral cortex

Vehicle
Telmisartan

Contralateral hippocampus

Vehicle
Telmisartan

Ipsilateral hippocampus

Vehicle
Telmisartan

PK

PDH

7.77 ± 0.45
5.84 ± 0.67*
7.70 ± 0.34
6.36 ± 0.32

HK2

GPR-81

Data are presented as relative ratio of tested gene/cyclophilin and shown as mean ± SE (n = 9–10 per group).
*P < 0.05 compared with Sham within the same drug treatment in the same brain area.
**P < 0.01 compared with Sham within the same drug treatment in the same brain area.
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